Fremanezumab helps prevent chronic migraine and improve QOL, claims study
Recent study has highlighted that fremanezumab demonstrated efficacy in the preventive treatment of chronic migraine and reduced headache impact in patients with comorbid depression. The findings have been put forth in Headache, The Journal of Head and Face Pain.
Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, has been approved for the preventive treatment of migraine in adults. CM and depression are highly comorbid.Researchers aimed to evaluate the efficacy of fremanezumab in patients with chronic migraine (CM) and moderate to severe depression.
For the study design, the 12-week, Phase 3 HALO trial randomized patients with CM to fremanezumab quarterly (675 mg/placebo/placebo), fremanezumab monthly (675/225/225 mg), or placebo was selected. Post hoc analyses evaluated the effects of fremanezumab in patients with moderate to severe depression (baseline 9-item Patient Health Questionnaire sum score ≥10) on monthly number of headache days of at least moderate severity; monthly migraine days; Patient Global Impression of Change (PGIC); 6-item Headache Impact Test (HIT-6) scores; and depression.
Results put forth some key facts.
- For the 219/1121 (19.5%) patients with moderate to severe depression at baseline, fremanezumab was associated with a significant reduction in monthly number of headache days of at least moderate severity for active treatment versus placebo (least-squares mean change ± standard error for quarterly dosing: −5.3 ± 0.77; for monthly dosing: −5.5 ± 0.72; and for placebo: −2.2 ± 0.81; both p < 0.001).
- More patients achieved a ≥50% reduction in headache days of at least moderate severity with fremanezumab (quarterly: 31/78 [39.7%]; monthly: 39/96 [40.6%]) than placebo (9/67 [13.4%]; both p < 0.001).
- Compared with placebo, fremanezumab improved PGIC and HIT-6 scores.
" Fremanezumab demonstrated a significant treatment benefit over placebo in reducing the monthly average number of headache days of at least moderate severity and migraine days in patients with CM and comorbid moderate to severe depression. Greater improvements in HRQoL, headache impact, and patient-reported overall health status were also seen with fremanezumab than with placebo. Fremanezumab may benefit patients with migraine and comorbid depression by reducing the frequency of migraine and headache days, decreasing disability, and improving HRQoL."the team opined.
For full article follow the link: https://doi.org/10.1111/head.14097
Source: Headache
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.